High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma

In response to the recently published article by Reidy-Lagunes et al., which deals with clinical response to mitotane treatment in advanced adrenocortical carcinoma and the toxicity associated with this treatment, this letter to the editor reports a case of mitotane-induced encephalopathy during a high-dose mitotane treatment in adrenocortical carcinoma.